oncocyte.com (OCX) - Bathi pungkasan

Decreased sustainability due to laboratory plastics creates risks reflected in the company's net income. The value of -0.06 determines the current status of the profit parameter. The financial growth of OncoCyte Corporation is based on the commercialization of DetermaRx and DetermaIO precision tests, while operational activities are strictly limited by FDA medical regulations regarding the disposal of biomaterials.

Bathi resik perusahaan oncocyte.com (OCX): kanggo periode 04.07.2022 - 18.06.2025

Rincian analitis lan laporan data perusahaan OncoCyte (OCX)

- rega saham lan target rega konsensus:

Bagan owah-owahan rega OncoCyte Inc|OCX - Target konsensus

- indikator kapitalisasi pasar:

Nilai pasar OncoCyte Inc|OCX - Nilai Perusahaan

- rincian valuasi buku bisnis:

Nilai Buku saben Saham OncoCyte|OCX - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku oncocyte.com|OCX - Total Aset Perusahaan

- indikator beban utang lan likuiditas:

- rincian bathi lan kelipatan pasar:

OCX - Bathi resik perusahaan

Ringkesan analisis perusahaan:OCX OncoCyte Inc

This metric determines net earnings per share, allowing the investor to assess the issuer's actual solvency and eliminate the risks of cash flow gaps. By analyzing the financial and business performance of OncoCyte Corporation (OCX) on GURU.Markets, one can see how the stable funding of an elite staff of geneticists converts into operational resilience during the development of innovative cancer diagnostic systems.

Pesaing utama